Oculis (NASDAQ:OCS) Given New $47.00 Price Target at HC Wainwright

Oculis (NASDAQ:OCS) had its price target raised by equities researchers at HC Wainwright from $44.00 to $47.00 in a report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 54.28% from the stock’s current price.

A number of other equities analysts have also recently commented on the stock. Wall Street Zen cut shares of Oculis from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a research report on Tuesday, April 21st. Needham & Company LLC lifted their target price on shares of Oculis from $36.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Finally, Stifel Nicolaus lifted their target price on shares of Oculis from $40.00 to $50.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $44.29.

Oculis Price Performance

Shares of Oculis stock traded down $2.19 on Tuesday, hitting $30.46. 316,977 shares of the company traded hands, compared to its average volume of 346,203. The firm’s 50-day simple moving average is $27.18 and its 200 day simple moving average is $24.33. The company has a current ratio of 5.96, a quick ratio of 5.96 and a debt-to-equity ratio of 0.01. The company has a market cap of $1.77 billion, a P/E ratio of -13.44 and a beta of 0.38. Oculis has a 12-month low of $16.00 and a 12-month high of $34.47.

Oculis (NASDAQ:OCS) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.07). The company had revenue of $0.26 million for the quarter, compared to analysts’ expectations of $0.25 million. Oculis had a negative net margin of 8,173.41% and a negative return on equity of 62.12%. Analysts expect that Oculis will post -2.17 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Oculis

A number of large investors have recently added to or reduced their stakes in the company. Himension Capital Singapore PTE. LTD. bought a new stake in Oculis in the 1st quarter worth $503,000. Koshinski Asset Management Inc. bought a new stake in Oculis in the 1st quarter worth $238,000. Y Intercept Hong Kong Ltd bought a new stake in Oculis in the 1st quarter worth $776,000. Perceptive Advisors LLC bought a new stake in Oculis in the 4th quarter worth $9,862,000. Finally, Millennium Management LLC bought a new stake in Oculis in the 4th quarter worth $312,000. Institutional investors own 22.30% of the company’s stock.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.